Artesunate should replace quinine as the drug of choice for treating malaria, according to an updated review of clinical trial results.
The updated review shows that using artesunate to treat people with severe malaria reduces the risk for death by 39% in adults and 24% in children, compared with quinine. In adults, deaths fell from 241 per 1,000 with quinine to 147 with artesunate. In children, deaths were reduced from 108 per 1,000 with quinine to 83 with artesunate.
Survival rates outweigh side-effects